Cited by 626Viral Infections and Immunology ResearchMechanical Circulatory Support DevicesTakotsubo Cardiomyopathy and Associated Phenomena

The DOI matches its Crossref record; 199 of the 199 references it cites were found in a registry or an index.

Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association

Open access
Kociol, Robb D., Cooper, Leslie T., Fang, James C., Moslehi, Javid J., Pang, Peter S., Sabe, Marwa A., Shah, Ravi V., Sims, Daniel B., Thiene, Gaetano, Vardeny, Orly, On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology·2020·Circulation

Abstract

Fulminant myocarditis (FM) is an uncommon syndrome characterized by sudden and severe diffuse cardiac inflammation often leading to death resulting from cardiogenic shock, ventricular arrhythmias, or multiorgan system failure. Historically, FM was almost exclusively diagnosed at autopsy. By definition, all patients with FM will need some form of inotropic or mechanical circulatory support to maintain end-organ perfusion until transplantation or recovery. Specific subtypes of FM may respond to immunomodulatory therapy in addition to guideline-directed medical care. Despite the increasing availability of circulatory support, orthotopic heart transplantation, and disease-specific treatments, patients with FM experience significant morbidity and mortality as a result of a delay in diagnosis and initiation of circulatory support and lack of appropriately trained specialists to manage the condition. This scientific statement outlines the resources necessary to manage the spectrum of FM, including extracorporeal life support, percutaneous and durable ventricular assist devices, transplantation capabilities, and specialists in advanced heart failure, cardiothoracic surgery, cardiac pathology, immunology, and infectious disease. Education of frontline providers who are most likely to encounter FM first is essential to increase timely access to appropriately resourced facilities, to prevent multiorgan system failure, and to tailor disease-specific therapy as early as possible in the disease process.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/cir.0000000000000745

Cites

199 of 199 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 199 references

Research works printed but not linked: 2

  1. 10.1161/CIRCHEARTFAILURE.112.000087 · DOI
  2. 10.1007/s10741-012-9358-3 · DOI · Paper page

Cited by

Sorted by citations

Items 601–626 of 626

Metadata

Authors
Kociol, R. D., Cooper, L. T., Fang, J. C., Moslehi, J. J., Pang, P. S., Sabe, M. A., Shah, R. V., Sims, D. B., Thiene, G., Vardeny, O., & On behalf of the American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology
Venue
Circulation
Published
2020-02-11
Volume
141
Issue
6
Pages
e69-e92
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2999324438
Cited by
625
References
199
Citations by year
2026: 78 · 2025: 69 · 2024: 98 · 2023: 100 · 2022: 121 · 2021: 91 · 2020: 66
FWCI
58.48
Type
journal article
Language
en
Open access
Locations
  • Circulation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Mechanical Circulatory Support Devices
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Takotsubo Cardiomyopathy and Associated Phenomena
Keywords
fulminant myocarditis, cardiogenic shock, ventricular arrhythmias, multiple organ failure, mechanical circulatory support, extracorporeal life support, ventricular assist devices, heart transplantation, immunomodulatory therapy, advanced heart failure, delayed diagnosis
MeSH terms
American Heart Association, Arrhythmias, Cardiac, Female, Humans, Multiple Organ Failure, Myocarditis, Shock, Cardiogenic, United States, Extracorporeal Membrane Oxygenation, Heart Transplantation, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review